FDA panel rejects testosterone patch for women on safety grounds

BMJ 2004; 329 doi: (Published 09 December 2004) Cite this as: BMJ 2004;329:1363
  1. Ray Moynihan
  1. Washington, DC

    A panel of advisers to the US Food and Drug Administration last week unanimously rejected an experimental testosterone patch as a treatment for women with sexual difficulties.

    Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.”

    The FDA had granted Procter & Gamble a fast track review of the testosterone patch, but the committee's unanimous …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial